<i id='397562F961'><strike id='397562F961'><tt id='397562F961'><pre id='397562F961'></pre></tt></strike></i> 
EQRx is done, sold for its cash.
The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.
advertisement
The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTED Log In
Alkermes shareholders re 
Why Charlie Gard's case is so disturbing to Americans 
Drug repurposing or repositioning? The language matters 
The most pressing bird flu mysteries scientists want answered 
In Memoriam: Notable people who died in 2023 
A virus, fished out of a lake, may have saved a man’s life 
Continuity nursing helped my family in our darkest PICU moments 
FDA authorizes Novavax’s updated Covid 
Jerome Adams on the need for new antivirals for Covid 
Elevance PBM president out as customers face prescription chaos 
Biden outlines 'new path' to provide student loan relief after Supreme Court rejection
Why Charlie Gard's case is so disturbing to Americans
In Memoriam: Notable people who died in 2023 
UnitedHealth CEO's Medicaid comments send insurer stocks diving 
Duchenne breakthrough therapy leaves behind pioneering families 
